Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 116

The DOI matches its Crossref record.

Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders

Coutinho, Maria, Santos, Juliana, Alves, Sandra·2016·International Journal of Molecular Sciences
DOI 10.3390/ijms17071065PMC PMC4964441
Open this paper in CoChat — free account

Abstract

Lysosomal storage diseases (LSDs) are a group of rare, life-threatening genetic disorders, usually caused by a dysfunction in one of the many enzymes responsible for intralysosomal digestion. Even though no cure is available for any LSD, a few treatment strategies do exist. Traditionally, efforts have been mainly targeting the functional loss of the enzyme, by injection of a recombinant formulation, in a process called enzyme replacement therapy (ERT), with no impact on neuropathology. This ineffectiveness, together with its high cost and lifelong dependence is amongst the main reasons why additional therapeutic approaches are being (and have to be) investigated: chaperone therapy; gene enhancement; gene therapy; and, alternatively, substrate reduction therapy (SRT), whose aim is to prevent storage not by correcting the original enzymatic defect but, instead, by decreasing the levels of biosynthesis of the accumulating substrate(s). Here we review the concept of substrate reduction, highlighting the major breakthroughs in the field and discussing the future of SRT, not only as a monotherapy but also, especially, as complementary approach for LSDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms17071065

Cites

Statistics

Figures

Figure 1 Schematic presentation of the Glycosphingolipids (GLS) biosynthesis, emphasizing the conversion of ceramide to glucosylceramide (GlcCer) via the action of UDP-glucose:N-acylsphingosine glucosyltransferase (ceramide glucosyltransferase, CGT), major target for substrate reduction approaches in GLS-storage diseases (*) (Adapted from [26]).
Figure 1 Schematic presentation of the Glycosphingolipids (GLS) biosynthesis, emphasizing the conversion of ceramide to glucosylceramide (GlcCer) via the action of UDP-glucose:N-acylsphingosine glucosyltransferase (ceramide glucosyltransferase, CGT), major target for substrate reduction approaches in GLS-storage diseases (*) (Adapted from [26]).CC BY · PubMed Central
Figure 2 Schematic presentation of the biosynthetic assembly of heparan sulfate (HS) and heparin (Hep) from GAG backbones through the action of several glycosyltransferases (adapted from [106]). Each glycosyltransferase requires the respective UDP-sugar as a donor substrate. Following the synthesis of specific core proteins, the synthesis of the so-called GAG-protein linkage region, GlcUA β1—3Gal β1—3Gal β1—4Xylβ1-O-, common to chondroitin sulfate/dermatan sulfate (CS/DS) and HS/Hep chains, is initiated by XylT, which transfers a Xyl residue from UDP-Xyl to the specific Ser residue in the endoplasmic reticulum, and is completed by the consecutive addition of each sugar by GalT-I, GalT-II, and GlcAT-I, which are common to the biosynthesis of both CS and HS, in the Golgi apparatus. The addition of 1–4-linked GlcNAc to the linkage region by GlcNAcT-I initiates the assembly of the HS repeating disaccharide region, (-4GlcNAcβ1—4GlcUAβ1-)n. Then, the chain polymerization of the HS chain is catalyzed by HS-GlcAT-II and GlcNAcT-II activities of HS polymerase, which is a heterocomplex of EXT1 and EXT2. After the formation of the heparan backbone, GAG chains are matured by sulfation at various positions and epimerization at GlcUA residues. Each enzyme (glycosyltransferase and/or epimerase) is described by its respective sugar symbol: β-xylosyltransferase (XylT); β-1,4-galactosyltransferase-I (GalT-I); β-1,3-galactosyltransferase-II (GalT-II); β-1,3-glucuronosyltransferases (GlcAT-I and GlcAT-II); and 1,4-N-acetylglucosaminyltransferase (GlcNAcT-I). Sulfotransferases involved in the chain modifications are not included.
Figure 2 Schematic presentation of the biosynthetic assembly of heparan sulfate (HS) and heparin (Hep) from GAG backbones through the action of several glycosyltransferases (adapted from [106]). Each glycosyltransferase requires the respective UDP-sugar as a donor substrate. Following the synthesis of specific core proteins, the synthesis of the so-called GAG-protein linkage region, GlcUA β1—3Gal β1—3Gal β1—4Xylβ1-O-, common to chondroitin sulfate/dermatan sulfate (CS/DS) and HS/Hep chains, is initiated by XylT, which transfers a Xyl residue from UDP-Xyl to the specific Ser residue in the endoplasmic reticulum, and is completed by the consecutive addition of each sugar by GalT-I, GalT-II, and GlcAT-I, which are common to the biosynthesis of both CS and HS, in the Golgi apparatus. The addition of 1–4-linked GlcNAc to the linkage region by GlcNAcT-I initiates the assembly of the HS repeating disaccharide region, (-4GlcNAcβ1—4GlcUAβ1-)n. Then, the chain polymerization of the HS chain is catalyzed by HS-GlcAT-II and GlcNAcT-II activities of HS polymerase, which is a heterocomplex of EXT1 and EXT2. After the formation of the heparan backbone, GAG chains are matured by sulfation at various positions and epimerization at GlcUA residues. Each enzyme (glycosyltransferase and/or epimerase) is described by its respective sugar symbol: β-xylosyltransferase (XylT); β-1,4-galactosyltransferase-I (GalT-I); β-1,3-galactosyltransferase-II (GalT-II); β-1,3-glucuronosyltransferases (GlcAT-I and GlcAT-II); and 1,4-N-acetylglucosaminyltransferase (GlcNAcT-I). Sulfotransferases involved in the chain modifications are not included.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 135

  1. Hers, 1965, Inborn lysosomal diseases, Gastroenterology, 48, 625, 10.1016/S0016-5085(65)80041-5 · DOI
  2. Barranger, J.A., and Cabrera-Salazar, M. (2007). From lysosomes to storage diseases and back: A personal reminiscence. Lysosomal Storage Disorders, Springer US. · DOI
  3. Deduve, 1964, From cytases to lysosomes, Fed. Proc., 23, 1045
  4. Fratantoni, 1969, The defect in hurler and hunter syndromes. II. Deficiency of specific factors involved in mucopolysaccharide degradation, Proc. Natl. Acad. Sci. USA, 64, 360, 10.1073/pnas.64.1.360 · DOI
  5. Coutinho, 2012, Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction, Mol. Genet. Metab., 105, 542, 10.1016/j.ymgme.2011.12.012 · DOI
  6. Desnick, 2012, Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges, Annu. Rev. Genom. Hum. Genet., 13, 307, 10.1146/annurev-genom-090711-163739 · DOI
  7. Brady, 1974, Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease, N. Engl. J. Med., 291, 989, 10.1056/NEJM197411072911901 · DOI
  8. Barton, 1990, Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease, Proc. Natl. Acad. Sci. USA, 87, 1913, 10.1073/pnas.87.5.1913 · DOI
  9. Barton, 1991, Replacement therapy for inherited enzyme deficiency—Macrophage-targeted glucocerebrosidase for Gaucher’s disease, N. Engl. J. Med., 324, 1464, 10.1056/NEJM199105233242104 · DOI
  10. Wegrzyn, 2007, Substrate deprivation therapy: A new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases, J. Appl. Genet., 48, 383, 10.1007/BF03195237 · DOI
  11. Wraith, 2007, Enzyme replacement therapy in patients who have Mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human α-l-iduronidase (laronidase), Pediatrics, 120, e37, 10.1542/peds.2006-2156 · DOI
  12. Wraith, 2004, Enzyme replacement therapy for Mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-l-iduronidase (laronidase), J. Pediatr., 144, 581, 10.1016/j.jpeds.2004.01.046 · DOI
  13. Kishnani, 2009, Early treatment with alglucosidase α prolongs long-term survival of infants with pompe disease, Pediatr. Res., 66, 329, 10.1203/PDR.0b013e3181b24e94 · DOI
  14. Deegan, 2012, Fabry disease, enzyme replacement therapy and the significance of antibody responses, J. Inherit. Metab. Dis., 35, 227, 10.1007/s10545-011-9400-y · DOI
  15. Pastores, 2014, A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: Safety and tolerability, Genet. Med. Off. J. Am. Coll. Med. Genet., 16, 359
  16. Broomfield, 2016, The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders, J. Inherit. Metab. Dis., 39, 499, 10.1007/s10545-016-9917-1 · DOI
  17. Fan, 2007, Active-site-specific chaperone therapy for fabry disease. Yin and yang of enzyme inhibitors, FEBS J., 274, 4962, 10.1111/j.1742-4658.2007.06041.x · DOI
  18. Feldhammer, M., Durand, S., and Pshezhetsky, A.V. (2009). Protein misfolding as an underlying molecular defect in Mucopolysaccharidosis III type C. PLoS ONE, 4. · DOI
  19. Pastores, 2006, A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders, Drugs R D, 7, 339, 10.2165/00126839-200607060-00003 · DOI
  20. Keeling, 2001, Gentamicin-mediated suppression of hurler syndrome stop mutations restores a low level of α-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation, Hum. Mol. Genet., 10, 291, 10.1093/hmg/10.3.291 · DOI
  21. Hein, 2004, α-l-iduronidase premature stop codons and potential read-through in Mucopolysaccharidosis type I patients, J. Mol. Biol., 338, 453, 10.1016/j.jmb.2004.03.012 · DOI
  22. Brooks, 2006, Stop-codon read-through for patients affected by a lysosomal storage disorder, Trends Mol. Med., 12, 367, 10.1016/j.molmed.2006.06.001 · DOI
  23. Matos, 2014, Therapeutic strategies based on modified U1 snRNAs and chaperones for sanfilippo C splicing mutations, Orphanet J. Rare Dis., 9, 180, 10.1186/s13023-014-0180-y · DOI
  24. Matos, 2015, Functional analysis of splicing mutations in the IDS gene and the use of antisense oligonucleotides to exploit an alternative therapy for MPS II, Biochim. Biophys. Acta, 1852, 2712, 10.1016/j.bbadis.2015.09.011 · DOI
  25. Warnock, D.G., Bichet, D.G., Holida, M., Goker-Alpan, O., Nicholls, K., Thomas, M., Eyskens, F., Shankar, S., Adera, M., and Sitaraman, S. (2015). Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase a in fabry patients when co-administered with infused agalsidase. PLoS ONE, 10. · DOI
  26. Xu, 2015, Coformulation of a novel human α-galactosidase a with the pharmacological chaperone AT1001 leads to improved substrate reduction in fabry mice, Mol. Ther. J. Am. Soc. Gene Ther., 23, 1169, 10.1038/mt.2015.87 · DOI
  27. Radin, 1996, Treatment of Gaucher disease with an enzyme inhibitor, Glycoconj. J., 13, 153, 10.1007/BF00731489 · DOI
  28. Platt, 2003, Substrate reduction therapy in mouse models of the glycosphingolipidoses, Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 358, 947
  29. Ichikawa, 1998, Glucosylceramide synthase and glycosphingolipid synthesis, Trends Cell Biol., 8, 198, 10.1016/S0962-8924(98)01249-5 · DOI
  30. Sandhoff, 2003, Biosynthesis and degradation of mammalian glycosphingolipids, Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 358, 847
  31. Schapiro, 1998, pH-independent retrograde targeting of glycolipids to the golgi complex, Am. J. Physiol., 274, C319, 10.1152/ajpcell.1998.274.2.C319 · DOI
  32. Sandhoff, 1993, Ganglioside metabolism. Enzymology, topology, and regulation, J. Biol. Chem., 268, 5341, 10.1016/S0021-9258(18)53324-X · DOI
  33. Sandhoff, 1997, Biochemistry of glycosphingolipid degradation, Clin. Chim. Acta Int. J. Clin. Chem., 266, 51, 10.1016/S0009-8981(97)00166-6 · DOI
  34. Sandhoff, 1994, Intracellular trafficking of glycosphingolipids: Role of sphingolipid activator proteins in the topology of endocytosis and lysosomal digestion, FEBS Lett., 346, 103, 10.1016/0014-5793(94)00282-7 · DOI
  35. Sandhoff, 1996, Topology of glycosphingolipid degradation, Trends Cell Biol., 6, 98, 10.1016/0962-8924(96)80999-8 · DOI
  36. Neufeld, 1991, Lysosomal storage diseases, Annu. Rev. Biochem., 60, 257, 10.1146/annurev.bi.60.070191.001353 · DOI
  37. Butters, 2005, Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses, Glycobiology, 15, 43R, 10.1093/glycob/cwi076 · DOI
  38. Platt, 1994, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J. Biol. Chem., 269, 8362, 10.1016/S0021-9258(17)37202-2 · DOI
  39. Platt, 1994, N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, J. Biol. Chem., 269, 27108, 10.1016/S0021-9258(18)47132-3 · DOI
  40. Aerts, 2006, Substrate reduction therapy of glycosphingolipid storage disorders, J. Inherit. Metab. Dis., 29, 449, 10.1007/s10545-006-0272-5 · DOI
  41. Dwek, 2002, Targeting glycosylation as a therapeutic approach, Rev. Drug Discov., 1, 65, 10.1038/nrd708 · DOI
  42. Butters, 2003, Therapeutic applications of imino sugars in lysosomal storage disorders, Curr. Top. Med. Chem., 3, 561, 10.2174/1568026033452483 · DOI
  43. Butters, 2003, Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders, Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 358, 927
  44. Barranger, J.A., and Cabrera-Salazar, M.A. (2007). Substrate reduction therapy. Lysosomal Storage Disorders, Springer US. · DOI
  45. Yamanaka, 1994, Targeted disruption of the hexa gene results in mice with biochemical and pathologic features of tay-sachs disease, Proc. Natl. Acad. Sci. USA, 91, 9975, 10.1073/pnas.91.21.9975 · DOI
  46. Platt, 1997, Prevention of lysosomal storage in tay-sachs mice treated with N-butyldeoxynojirimycin, Science, 276, 428, 10.1126/science.276.5311.428 · DOI
  47. Sango, 1995, Mouse models of tay-sachs and sandhoff diseases differ in neurologic phenotype and ganglioside metabolism, Nat. Genet., 11, 170, 10.1038/ng1095-170 · DOI · Paper page
  48. Ashe, K.M., Bangari, D., Li, L., Cabrera-Salazar, M.A., Bercury, S.D., Nietupski, J.B., Cooper, C.G., Aerts, J.M., Lee, E.R., and Copeland, D.P. (2011). Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of sandhoff disease. PLoS ONE, 6. · DOI
  49. Cox, 2000, Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis, Lancet, 355, 1481, 10.1016/S0140-6736(00)02161-9 · DOI
  50. Elstein, 2004, Sustained therapeutic effects of oral miglustat (zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease, J. Inherit. Metab. Dis., 27, 757, 10.1023/B:BOLI.0000045756.54006.17 · DOI
  51. Schiffmann, 2008, Randomized, controlled trial of miglustat in Gaucher’s disease type 3, Ann. Neurol., 64, 514, 10.1002/ana.21491 · DOI
  52. Bennett, 2013, Gaucher disease and its treatment options, Ann. Pharmacother., 47, 1182, 10.1177/1060028013500469 · DOI
  53. Nietupski, 2012, Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice, Mol. Genet. Metab., 105, 621, 10.1016/j.ymgme.2012.01.020 · DOI
  54. Ridley, 2013, β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology, J. Biol. Chem., 288, 26052, 10.1074/jbc.M113.463562 · DOI
  55. Mistry, 2014, Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease, Proc. Natl. Acad. Sci. USA, 111, 4934, 10.1073/pnas.1400768111 · DOI
  56. Marques, A.R., Aten, J., Ottenhoff, R., van Roomen, C.P., Herrera Moro, D., Claessen, N., Vinueza Veloz, M.F., Zhou, K., Lin, Z., and Mirzaian, M. (2015). Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice. PLoS ONE, 10. · DOI
  57. Alfonso, 2005, Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations, Blood Cells Mol. Dis., 35, 268, 10.1016/j.bcmd.2005.05.007 · DOI
  58. Malinowska, 2015, Combined therapies for lysosomal storage diseases, Curr. Mol. Med., 15, 746, 10.2174/1566524015666150921105658 · DOI
  59. Ichikawa, 1996, Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis, Proc. Natl. Acad. Sci. USA, 93, 4638, 10.1073/pnas.93.10.4638 · DOI
  60. Vunnam, 1980, Analogs of ceramide that inhibit glucocerebroside synthetase in mouse brain, Chem. Phys. Lipids, 26, 265, 10.1016/0009-3084(80)90057-2 · DOI
  61. Shayman, 2013, The design and clinical development of inhibitors of glycosphingolipid synthesis: Will invention be the mother of necessity?, Trans. Am. Clin. Climatol. Assoc., 124, 46
  62. Lee, 1999, Fluorobenzamidrazone thrombin inhibitors: Influence of fluorine on enhancing oral absorption, Bioorg. Med. Chem. Lett., 9, 2483, 10.1016/S0960-894X(99)00412-6 · DOI
  63. Abe, 2000, Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase, Kidney Int., 57, 446, 10.1046/j.1523-1755.2000.00864.x · DOI
  64. Abe, 2000, Reduction of globotriaosylceramide in fabry disease mice by substrate deprivation, J. Clin. Investig., 105, 1563, 10.1172/JCI9711 · DOI
  65. Shayman, 2010, Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease, Drugs Future, 35, 613, 10.1358/dof.2010.35.8.1505566 · DOI
  66. Brumshtein, 2007, Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid β-glucosidase: Insights into the mechanism of chemical chaperone action in Gaucher disease, J. Biol. Chem., 282, 29052, 10.1074/jbc.M705005200 · DOI
  67. Duque, 2009, Promising results of the chaperone effect caused by imino sugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease, Blood Cells Mol. Dis., 42, 159, 10.1016/j.bcmd.2008.11.002 · DOI
  68. Peterschmitt, 2011, Safety, tolerability, and pharmacokinetics of eliglustat tartrate (genz-112638) after single doses, multiple doses, and food in healthy volunteers, J. Clin. Pharmacol., 51, 695, 10.1177/0091270010372387 · DOI
  69. Lukina, 2010, A phase 2 study of eliglustat tartrate (genz-112638), an oral substrate reduction therapy for Gaucher disease type 1, Blood, 116, 893, 10.1182/blood-2010-03-273151 · DOI
  70. Lukina, 2010, Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (genz-112638) treatment: 2-year results of a phase 2 study, Blood, 116, 4095, 10.1182/blood-2010-06-293902 · DOI
  71. Lukina, 2014, Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment, Blood Cells Mol. Dis., 53, 274, 10.1016/j.bcmd.2014.04.002 · DOI
  72. Cox, 2010, Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases, Curr. Opin. Investig. Drugs, 11, 1169
  73. Cox, 2015, Innovative treatments for lysosomal diseases, Best Pract. Res. Clin. Endocrinol. Metab., 29, 275, 10.1016/j.beem.2015.01.001 · DOI
  74. Kamath, 2014, Skeletal improvement in patients with Gaucher disease type 1: A phase 2 trial of oral eliglustat, Skelet. Radiol., 43, 1353, 10.1007/s00256-014-1891-9 · DOI
  75. Mistry, 2015, Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: The engage randomized clinical trial, JAMA, 313, 695, 10.1001/jama.2015.459 · DOI
  76. Belmatoug, N., Di Rocco, M., Fraga, C., Giraldo, P., Hughes, D., Lukina, E., Maison-Blanche, P., Merkel, M., Niederau, C., and Plckinger, U. (2016). Management and monitoring recommendations for the use of eliglustat in adults with type 1 gaucher disease in europe. Eur. J. Intern. Med. · DOI
  77. Platt, 2014, Sphingolipid lysosomal storage disorders, Nature, 510, 68, 10.1038/nature13476 · DOI
  78. Cabrera-Salazar, M.A., Deriso, M., Bercury, S.D., Li, L., Lydon, J.T., Weber, W., Pande, N., Cromwell, M.A., Copeland, D., and Leonard, J. (2012). Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS ONE, 7. · DOI
  79. Kanfer, 1975, The Gaucher mouse, Biochem. Biophys. Res. Commun., 67, 85, 10.1016/0006-291X(75)90286-7 · DOI
  80. Sun, 2010, Neuronopathic Gaucher disease in the mouse: Viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits, Hum. Mol. Genet., 19, 1088, 10.1093/hmg/ddp580 · DOI
  81. Marshall, 2016, CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease, Mol. Ther. J. A Soc. Gene Ther., 24, 1019, 10.1038/mt.2016.53 · DOI
  82. Speak, 2008, Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis, Mol. Genet. Metab., 94, 204, 10.1016/j.ymgme.2008.02.005 · DOI
  83. Kasperzyk, 2005, Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice, J. Lipid Res., 46, 744, 10.1194/jlr.M400411-JLR200 · DOI
  84. Jeyakumar, 1999, Delayed symptom onset and increased life expectancy in sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc. Natl. Acad. Sci. USA, 96, 6388, 10.1073/pnas.96.11.6388 · DOI
  85. Baek, 2008, N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff disease mice, Neurochem. Int., 52, 1125, 10.1016/j.neuint.2007.12.001 · DOI
  86. Masciullo, 2010, Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type sandhoff: Results of a 3-year follow-up, J. Inherit. Metab. Dis., 33, S355, 10.1007/s10545-010-9186-3 · DOI
  87. Burrow, T.A., and Grabowski, G.A. (2012). Emerging treatments and future outcomes. Lysosomal Storage Disorders—A Practical Guide, John Wiley & Sons, Ltd.. [1th ed.].
  88. Zervas, 2001, Critical role for glycosphingolipids in Niemann-Pick disease type c, Curr. Biol., 11, 1283, 10.1016/S0960-9822(01)00396-7 · DOI
  89. Patterson, 2007, Miglustat for treatment of Niemann-Pick C disease: A randomised controlled study, Lancet Neurol., 6, 765, 10.1016/S1474-4422(07)70194-1 · DOI
  90. Wraith, 2010, Miglustat in adult and juvenile patients with Niemann-Pick disease type C: Long-term data from a clinical trial, Mol. Genet. Metab., 99, 351, 10.1016/j.ymgme.2009.12.006 · DOI
  91. Pineda, 2010, Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: A case series, Mol. Genet. Metab., 99, 358, 10.1016/j.ymgme.2009.11.007 · DOI
  92. Chien, 2013, Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C, J. Inherit. Metab. Dis., 36, 129, 10.1007/s10545-012-9479-9 · DOI
  93. Fecarotta, 2015, Long term follow-up to evaluate the efficacy of miglustat treatment in italian patients with Niemann-Pick disease type C, Orphanet J. Rare Dis., 10, 22, 10.1186/s13023-015-0240-y · DOI
  94. Garatachea, 2015, Niemann-Pick disease treatment: A systematic review of clinical trials, Ann. Transl. Med., 3, 360
  95. Wegrzyn, 2010, Genistein: A natural isoflavone with a potential for treatment of genetic diseases, Biochem. Soc. Trans., 38, 695, 10.1042/BST0380695 · DOI
  96. Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). The mucopolysaccharidoses. The Metabolic Molecular Bases of Inherited Disease, McGraw-Hill Professional. [8th ed.].
  97. Coutinho, 2012, Glycosaminoglycan storage disorders: A review, Biochem. Res. Int., 2012, 471325, 10.1155/2012/471325 · DOI
  98. Piotrowska, 2006, Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses, Eur. J. Hum. Genet., 14, 846, 10.1038/sj.ejhg.5201623 · DOI
  99. Friso, 2010, Genistein reduces glycosaminoglycan levels in a mouse model of Mucopolysaccharidosis type II, Br. J. Pharmacol., 159, 1082, 10.1111/j.1476-5381.2009.00565.x · DOI
  100. Roberts, 2007, Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA, Mol. Genet. Metab., 92, 115, 10.1016/j.ymgme.2007.06.016 · DOI
  101. Roberts, 2006, Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of Mucopolysaccharidosis type IIIA, Pediatr. Res., 60, 309, 10.1203/01.pdr.0000233037.00707.da · DOI
  102. Roberts, 2010, Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine Mucopolysaccharidosis type IIIA, Mol. Genet. Metab., 101, 208, 10.1016/j.ymgme.2010.06.008 · DOI
  103. Piotrowska, 2008, Genistin-rich soy isoflavone extract in substrate reduction therapy for sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients, Curr. Ther. Res. Clin. Exp., 69, 166, 10.1016/j.curtheres.2008.04.002 · DOI
  104. Piotrowska, 2011, Changes in male reproductive system and mineral metabolism induced by soy isoflavones administered to rats from prenatal life until sexual maturity, Nutrition, 27, 372, 10.1016/j.nut.2010.03.010 · DOI
  105. Marucha, 2011, Improvement in the range of joint motion in seven patients with Mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (get it), Am. J. Med. Genet. Part A, 155A, 2257, 10.1002/ajmg.a.34146 · DOI
  106. Malinowska, 2009, Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide iiib mice, Mol. Genet. Metab., 98, 235, 10.1016/j.ymgme.2009.06.013 · DOI
  107. Malinowska, M., Wilkinson, F.L., Langford-Smith, K.J., Langford-Smith, A., Brown, J.R., Crawford, B.E., Vanier, M.T., Grynkiewicz, G., Wynn, R.F., and Wraith, J.E. (2010). Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS ONE, 5. · DOI
  108. Mizumoto, 2013, Human genetic disorders caused by mutations in genes encoding biosynthetic enzymes for sulfated glycosaminoglycans, J. Biol. Chem., 288, 10953, 10.1074/jbc.R112.437038 · DOI
  109. Dire, 1987, Acute exposure to rhodamine B, J. Toxicol. Clin. Toxicol., 25, 603, 10.3109/15563658708992660 · DOI
  110. Piotrowska, 2009, Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway, J. Biomed. Sci., 16, 26, 10.1186/1423-0127-16-26 · DOI
  111. Moskot, 2014, The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation, J. Biol. Chem., 289, 17054, 10.1074/jbc.M114.555300 · DOI
  112. Noh, 2014, Current and potential therapeutic strategies for mucopolysaccharidoses, J. Clin. Pharm. Ther., 39, 215, 10.1111/jcpt.12136 · DOI
  113. Andersson, 2004, Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of sandhoff disease, Neurobiol. Dis., 16, 506, 10.1016/j.nbd.2004.04.012 · DOI
  114. Andersson, 2000, N-butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo, Biochem. Pharmacol., 59, 821, 10.1016/S0006-2952(99)00384-6 · DOI
  115. Ramachandran, 2013, Rna interference—A silent but an efficient therapeutic tool, Appl. Biochem. Biotechnol., 169, 1774, 10.1007/s12010-013-0098-1 · DOI
  116. Diallo, 2003, Long endogenous dsrnas can induce complete gene silencing in mammalian cells and primary cultures, Oligonucleotides, 13, 381, 10.1089/154545703322617069 · DOI
  117. Chabas, 2006, Rnai-mediated inhibition of the glucosylceramide synthase (GCS) gene: A preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases, Blood Cells Mol. Dis., 37, 197, 10.1016/j.bcmd.2006.07.002 · DOI
  118. Dziedzic, 2010, Impairment of glycosaminoglycan synthesis in Mucopolysaccharidosis type IIIA cells by using siRNA: A potential therapeutic approach for sanfilippo disease, Eur. J. Hum. Genet., 18, 200, 10.1038/ejhg.2009.144 · DOI
  119. Canals, 2015, EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for sanfilippo C syndrome, Sci. Rep., 5, 13654, 10.1038/srep13654 · DOI
  120. Mehta, A., Beck, M., and Sunder-Plassmann, G. (2006). “Animal models of lysosomal storage diseases: Their development and clinical relevance” in fabry disease: Perspectives from 5 years of fos. Oxford Pharmagenesis, Oxford Pharmagenesis.
  121. Burrow, T.A., and Grabowski, G.A. (2012). “Emerging Treatments and Future Outcomes” in Lysosomal Storage Disorders—A Practical Guide, Wiley. [1st ed.].
  122. Capablo, 2007, Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination, Epilepsia, 48, 1406, 10.1111/j.1528-1167.2007.01074.x · DOI
  123. Bour, 2008, Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III, J. Inherit. Metab. Dis., 31, 745, 10.1007/s10545-008-0873-2 · DOI
  124. Marshall, 2010, Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy, J. Inherit. Metab. Dis., 33, 281, 10.1007/s10545-010-9072-z · DOI
  125. Marshall, J., Ashe, K.M., Bangari, D., McEachern, K., Chuang, W.L., Pacheco, J., Copeland, D.P., Desnick, R.J., Shayman, J.A., and Scheule, R.K. (2010). Substrate reduction augments the efficacy of enzyme therapy in a mouse model of fabry disease. PLoS ONE, 5. · DOI
  126. Jeyakumar, 2001, Enhanced survival in sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation, Blood, 97, 327, 10.1182/blood.V97.1.327 · DOI
  127. Pabon, 2015, Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with sandhoff disease, Eur. J. Med. Genet., 58, 180, 10.1016/j.ejmg.2014.12.009 · DOI
  128. Shapiro, 2009, Miglustat in late-onset tay-sachs disease: A 12-month, randomized, controlled clinical study with 24 months of extended treatment, Genet. Med. Off. J. Am. Coll. Med. Genet., 11, 425
  129. Denny, 2010, Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult sandhoff disease mice, J. Neurochem., 113, 1525, 10.1111/j.1471-4159.2010.06733.x · DOI
  130. Williams, 2014, Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice, Neurobiol. Dis., 67, 9, 10.1016/j.nbd.2014.03.001 · DOI
  131. Narajczyk, 2012, Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis, Acta Biochim. Pol., 59, 693, 10.18388/abp.2012_2112 · DOI
  132. Piotrowska, 2011, Substrate reduction therapies for mucopolysaccharidoses, Curr. Pharm. Biotechnol., 12, 1860, 10.2174/138920111798376932 · DOI
  133. Venier, 2012, Miglustat as a therapeutic agent: Prospects and caveats, J. Med. Genet., 49, 591, 10.1136/jmedgenet-2012-101070 · DOI
  134. Wegrzyn, 2012, Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses, Arch. Immunol. Ther. Exp., 60, 461, 10.1007/s00005-012-0195-9 · DOI
  135. Mehta, A.B., and Winchester, B. (2012). Lysosomal Storage Disorders: A Practical Guide, Wiley. · DOI

Cited by

Metadata

Authors
Coutinho, M., Santos, J., & Alves, S.
Affiliations
Department of Human Genetics, Research and Development Unit, National Health Institute Doutor Ricardo Jorge, Rua Alexandre Herculano, 321 4000-055 Porto, Portugal
ORCID
Coutinho, Maria
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2016-07-04
Volume
17
Issue
7
Pages
1065
ISSN
1422-0067
DOI
10.3390/ijms17071065
PMC
PMC4964441
Cited by
116
References
0
Language
en
Update notices
correction (2016-07-04)
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review